- Home
- XXII vs BJDX Comparison
XXII vs BJDX Comparison
Compare XXII & BJDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XXII
- BJDX
- Stock Information
- Founded
- XXII 1998
- BJDX 2015
- Country
- XXII United States
- BJDX United States
- Employees
- XXII N/A
- BJDX N/A
- Industry
- XXII Medicinal Chemicals and Botanical Products
- BJDX Medical Specialities
- Sector
- XXII Health Care
- BJDX Health Care
- Exchange
- XXII Nasdaq
- BJDX Nasdaq
- Market Cap
- XXII 2.0M
- BJDX 2.0M
- IPO Year
- XXII N/A
- BJDX 2021
- Fundamental
- Price
- XXII $1.65
- BJDX $1.43
- Analyst Decision
- XXII
- BJDX
- Analyst Count
- XXII 0
- BJDX 0
- Target Price
- XXII N/A
- BJDX N/A
- AVG Volume (30 Days)
- XXII 200.6K
- BJDX 5.2M
- Earning Date
- XXII 08-14-2025
- BJDX 08-07-2025
- Dividend Yield
- XXII N/A
- BJDX N/A
- EPS Growth
- XXII N/A
- BJDX N/A
- EPS
- XXII N/A
- BJDX N/A
- Revenue
- XXII $21,362,000.00
- BJDX N/A
- Revenue This Year
- XXII $22.41
- BJDX N/A
- Revenue Next Year
- XXII $76.35
- BJDX $55.56
- P/E Ratio
- XXII N/A
- BJDX N/A
- Revenue Growth
- XXII N/A
- BJDX N/A
- 52 Week Low
- XXII $1.72
- BJDX $1.26
- 52 Week High
- XXII $1,571.13
- BJDX $12.45
- Technical
- Relative Strength Index (RSI)
- XXII 20.98
- BJDX 48.69
- Support Level
- XXII $1.72
- BJDX $1.26
- Resistance Level
- XXII $2.45
- BJDX $1.48
- Average True Range (ATR)
- XXII 0.11
- BJDX 0.08
- MACD
- XXII 0.16
- BJDX 0.01
- Stochastic Oscillator
- XXII 0.00
- BJDX 61.54
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
About BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.